Team:Freiburg/Content/Team/Members
From 2014.igem.org
(Difference between revisions)
Line 1: | Line 1: | ||
- | <html> | + | <!-- hier ändern https://2014.igem.org/Team:Freiburg/Content/Team/Members --> |
+ | <html lang="en"> | ||
+ | <head> | ||
+ | <title>The AcCELLerator</title> | ||
+ | <link rel="stylesheet" type="text/css" href="styles.css"> | ||
+ | </head> | ||
+ | <body> | ||
+ | <section id="Vector"> | ||
+ | <h1>Team</h1> | ||
+ | </section> | ||
+ | <section> | ||
+ | <h2 id="Team-Members">Members</h2> | ||
+ | <div class="row category-row"> | ||
+ | <div class="col-sm-6"> | ||
+ | <p>We succeed to stably integrate our gene of interest into the genome of target cells by using a viral vector derived from the murine leukemia virus. The advantages of this vector are: its specificity for murine cells, making the viral work safe and easy; a very high efficiency for infection; and the ability of stable gene transfer into the genomes of target cells. Here we present results on these three qualities of our viral vector and how we optimized virus production and cell infection.</p> | ||
+ | </div> | ||
+ | <div class="col-sm-6"> | ||
+ | <figure> | ||
+ | <img src="https://static.igem.org/mediawiki/2014/c/c6/Group_picture_freiburg_01.JPG"> | ||
+ | <figcaption> | ||
+ | <p class="header">Team</p> | ||
+ | </figcaption> | ||
+ | </figure> | ||
+ | </div> | ||
+ | </div> | ||
+ | </section> | ||
- | |||
- | < | + | </body> |
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | |||
</html> | </html> |
Revision as of 16:30, 8 October 2014
Team
Members
We succeed to stably integrate our gene of interest into the genome of target cells by using a viral vector derived from the murine leukemia virus. The advantages of this vector are: its specificity for murine cells, making the viral work safe and easy; a very high efficiency for infection; and the ability of stable gene transfer into the genomes of target cells. Here we present results on these three qualities of our viral vector and how we optimized virus production and cell infection.